Brief: Agenus Provides Corporate Update And First Quarter 2023 Financial Results
09/05/2023 13:49
May 9 (Reuters) - Agenus Inc AGEN.O :
* AGENUS PROVIDES CORPORATE UPDATE AND FIRST QUARTER 2023
FINANCIAL RESULTS
* AGENUS INC - PHASE II ACTIVATE TRIALS EXPECTED TO FULLY
ENROLL
IN SECOND HALF OF 2023
* AGENUS INC - AGEN2373 MONOTHERAPY DATA TO BE PRESENTED AT
ASCO
IN JUNE 2023
* AGENUS INC - BALSTILIMAB/ZALIFRELIMAB DATA IN TREATMENT OF
SARCOMA TO BE PRESENTED AT ASCO ORAL SESSION IN JUNE 2023
* AGENUS INC - ENDED Q1 WITH A CASH, CASH EQUIVALENT AND
SHORT-TERM INVESTMENT BALANCE OF $189.2 MILLION
Source text for Eikon: ID:nBw3R2YDha
Further company coverage: AGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Agenus
See all newsBrief: Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026
Brief: Armenia Grants First Marketing Authorizations For Agenus’ Bot+Bal In Previously Treated Mss Metastatic Colorectal Cancer
Brief: Agenus - Unit Enters Second Loan Modification Agreement With Ocean 1181 On Aug 12, 2026 - SEC Filing
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Q2 revenue rises on access and royalty income